These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 26981618)
1. Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics. Henry SP; Seguin R; Cavagnaro J; Berman C; Tepper J; Kornbrust D Nucleic Acid Ther; 2016 Aug; 26(4):210-5. PubMed ID: 26981618 [TBL] [Abstract][Full Text] [Related]
2. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529 [TBL] [Abstract][Full Text] [Related]
4. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940 [TBL] [Abstract][Full Text] [Related]
5. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591 [TBL] [Abstract][Full Text] [Related]
6. Phosphorothioate oligonucleotides: effectiveness and toxicity. Iannitti T; Morales-Medina JC; Palmieri B Curr Drug Targets; 2014; 15(7):663-73. PubMed ID: 24655142 [TBL] [Abstract][Full Text] [Related]
7. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics. Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186 [TBL] [Abstract][Full Text] [Related]
8. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry SP; Templin MV; Gillett N; Rojko J; Levin AA Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680 [TBL] [Abstract][Full Text] [Related]
9. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Frazier KS; Sobry C; Derr V; Adams MJ; Besten CD; De Kimpe S; Francis I; Gales TL; Haworth R; Maguire SR; Mirabile RC; Mullins D; Palate B; Doorten YP; Ridings JE; Scicchitano MS; Silvano J; Woodfine J Toxicol Pathol; 2014 Jul; 42(5):923-35. PubMed ID: 24292388 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]